Personalised risk prediction tools for cryptococcal meningitis mortality to guide treatment stratification; a pooled analysis of two randomised-controlled trials
Thomas HA Samuels,Sile F Molloy,David S Lawrence,Angela Loyse,Cecilia Kanyama,Robert S Heyderman,Wai Shing Lai,Sayoki Mfinanga,Sokoine Lesikari,Duncan Chanda,Charles Kounfack,Elvis Temfack,Olivier Lortholary,Mina C Hosseinipour,Adrienne K Chan,David B Meya,David R Boulware,Henry C Mwandumba,Graeme Meintjes,Conrad Muzoora,Mosepele Mosepele,Chiratidzo E Ndhlovu,Nabila Youssouf,Thomas S Harrison,Joseph N Jarvis,Rishi K Gupta
DOI: https://doi.org/10.1101/2024.07.10.24310212
2024-07-10
Abstract:Background
Cryptococcal meningitis is a leading cause of adult community-acquired meningitis in sub-Saharan Africa with high mortality rates in the first 10 weeks post diagnosis. Practical tools to stratify mortality risk may help to tailor effective treatment strategies.
Methods
We pooled individual-level data from two randomised-controlled trials of HIV-associated cryptococcal meningitis across eight sub-Saharan African countries (ACTA, ; Ambition-cm, ). We used this pooled dataset to develop and validate multivariable logistic regression models for 2-week and 10-week mortality. Candidate predictor variables were specified a priori. Basic models were developed using only predictors available in resource-limited settings; Research models were developed from all available predictors. We used internal-external cross-validation to evaluate performance across countries within the development cohort, before validation of discrimination, calibration and net benefit in held-out data from Malawi (Ambition-cm trial). We also evaluated whether treatment effects in the trials were heterogenous by predicted mortality risk.
Findings
We included 1488 participants, of whom 236 (15.9%) and 469 (31.5%) met the 2-week and 10-week mortality outcomes, respectively. In the development cohort (n=1263), five variables were selected into the basic model (haemoglobin, neutrophil count, Eastern Cooperative Oncology Group performance status, Glasgow coma scale and treatment regimen), with two additional variables in the research model (cerebrospinal fluid quantitative culture and opening pressure) for 2-week mortality. During internal-external cross-validation, both models showed consistent discrimination across countries (pooled areas under the receiver operating characteristic curves (AUROCs) 0.75 (95% CI 0.68-0.82) and 0.78 (0.75-0.82) for the Basic and Research 2-week mortality models, respectively), with some variation in calibration between sites. Performance was similar in held-out validation (n=225), with the models demonstrating higher net benefit to inform decision-making than alternative approaches including a pre-existing comparator model. In exploratory analyses, treatment effects varied by predicted mortality risk, with a trend towards lower absolute and relative mortality for a single high-dose liposomal Amphotericin B-based regimen (in comparison to 1-week Amphotericin B deoxycholate plus flucytosine) among lower risk participants in the Ambition-cm trial.
Interpretation
Both models accurately predict mortality, were generalisable across African trial settings, and have potential to be incorporated into future treatment stratification approaches in low and middle-income settings.
Funding:
MRC, United Kingdom (100504); ANRS, France (ANRS12275); SIDA, Sweden (TRIA2015-1092); Wellcome/MRC/UKAID Joint Global Health Trials (MR/P006922/1); European DCCT Partnership; NIHR, United Kingdom through a Global Health Research Professorship to JNJ (RP-2017-08-ST2-012) and a personal Fellowship to RKG (NIHR302829).
Infectious Diseases (except HIV/AIDS)